Preliminary results of the pivotal randomized LUNAR trial showed Novocure's Tumor Treating Fields (TTFields) therapy improves overall survival in patients with stage 4 non-small cell lung cancer (NSCLC).
The company announced that the trial met its primary efficacy endpoint on 5 January.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?